anti-SARS-CoV-2 virus inactivated plasma  / Wuhan University 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
anti-SARS-CoV-2 virus inactivated plasma  / Wuhan University
ChiCTR2000030929: A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)

Not yet recruiting
N/A
60
China
Anti-SARS-CoV-2 virus inactivated plasma ;Ordinary plasma
Renmin Hospital of Wuhan University; Renmin Hospital of Wuhan University, Sinopharm Wuhan Blood Products Co., Ltd.
Novel Coronavirus Pneumonia (COVID-19)
 
 

Download Options